PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Weitz & Luxenberg

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Weitz & Luxenberg Responds to Report of Panelists’ Financial Ties to Stents - A Bloomberg News article revealed that six physicians who have been advising U.S. regulators on the safety of stents, have financial ties to Johnson & Johnson, maker of the Cypher (Cordis) Stent, and Boston Scientific Corp., maker of the Taxus Stents
Weitz & Luxenberg Responds to Report of Panelists’ Financial Ties to Stents

 

NewswireToday - /newswire/ - New York City, NY, United States, 2006/12/11 - A Bloomberg News article revealed that six physicians who have been advising U.S. regulators on the safety of stents, have financial ties to Johnson & Johnson, maker of the Cypher (Cordis) Stent, and Boston Scientific Corp., maker of the Taxus Stents.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Financial/Legal/Venture Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

As the Food and Drug Administration panel converged last week in Washington to review the incidence of lethal blood clots linked to drug-eluting stents, a Bloomberg News article revealed that six physicians who have been advising U.S. regulators on the matter, have financial ties to Johnson & Johnson, maker of the Cypher (Cordis) Stent, and Boston Scientific Corp., maker of the Taxus Express2 Paclitaxel-Eluting Coronary Stent. The panel has just recommended allowing those dangerous products to remain on the market.

Of today’s FDA decision, Paul J. Pennock, director of the drug and medical device litigation unit at Weitz & Luxenberg, P.C., said, “It is unsurprising that the Panel would vote in favor of the stents despite the strong evidence that drug-eluting stents carry life-threatening risks.”

Pennock has handled many high-profile cases dedicated to the public's welfare, among them litigation related to the dangerous contact-lens solution ReNu with MoistureLoc, manufactured by Bausch & Lomb.

Weitz & Luxenberg, one of the leading plaintiffs’ personal injury litigation law firms in America, has been following the research on late in-stent thrombosis—blot clots occurring within the stent more than 30 days after implantation. Researchers have found that the clots can lead to heart attacks, a repeat revascularization procedure, open-heart surgery and even death.

Most recently, an analysis by the Cleveland Clinic Foundation, published November 29th in the American Journal of Medicine, found that blood clots are four to five times more likely to develop in patients with drug-coated stents, compared to the older, bare-metal versions. Data presented at the hearing from a comprehensive Swedish Registry, which followed outcomes for three years, showed that after six months, a significant increase in the rate of blood clots was associated with a corresponding increase in the rate of heart attack and death; a fact that both device manufacturers have long disputed. It would appear that some of the conflicted members of the panel ignored this significant evidence.

Given the seriousness of medical issue before the panel, the FDA’s decision to use physicians who have monetary stakes in the products under review, is a betrayal of the public’s trust. In 2004, a similar predicament occurred in a decision to allow Vioxx back onto the market. Nearly all of the panelists with financial ties to the drug companies who made that class of pharmaceuticals reportedly voted to allow it; however, in that case, the FDA later chose to reject the advice of compromised physicians.

People who have been harmed by drug-coated Taxus or Cypher stents can contact Weitz & Luxenberg. Interested parties should call the Client Relations department or via email.

About Weitz & Luxenberg, P.C.

Weitz & Luxenberg (weitzlux.com), founded in 1986, is one of the leading plaintiffs’, mass torts, product liability, and personal injury litigation law firms in America. We have tried other pharmaceutical product liability cases in the New Jersey mass tort court, including the noted $13.5 million victory in the Vioxx case McDarby v. Merck (docket no. ATLL129605), earlier this year, including what is considered to be the first punitive-damage verdict in New Jersey against a pharmaceutical company. We are involved in the other New Jersey mass torts involving dangerous drugs, including PPA, Propulsid, Accutane, Vioxx and Bextra/Celebrex and Seroquel. The firm has also played leading roles in national and local litigations involving asbestos, silicone breast implants, and the pharmaceutical products DES, Rezulin, and Baycol as well as medical malpractice, and general negligence, among others. A forerunner in the legal fight against environmental polluters, Weitz & Luxenberg has worked with clients harmed by MTBE, mercury and trichloroethylene, among other toxins.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Financial/Legal/Venture Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Weitz & Luxenberg

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Financial/Legal/Venture articles,
CATCH Visitors via Your Competitors Announcements!


Weitz & Luxenberg Responds to Report of Panelists’ Financial Ties to Stents

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Client Relations - WeitzLux.com 
1-800-476-6070 clientrelations[.]weitzlux.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Weitz & Luxenberg securities in any jurisdiction including any other companies listed or named in this release.

Financial/Legal/Venture via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Weitz & Luxenberg / Company Profile


Read Financial/Legal/Venture Most Recent Related Newswires:

Elite Capital & Co. Acquired the Prestigious Domain Name Elite.Capital
LexisNexis Implements Critical Mention’s Broadcast Media Monitoring API
LexisNexis Partners with Uptime Legal to Host PCLaw and Time Matters in the Cloud
HSTM Historic Stocks Market Index Rose 1.40% in the First Half-year of 2017
Acquisition Assessments Arouse the Interest of TPA Business Owners Looking to Sell
TRA Hires Programmer Analyst to Enhance IT Department
Bosnia, Privatized Krajina Insurance Osiguranje is Nationalized - Investors Start Arbitration
TRA Announces Acquisition of Retirement Planning, Inc.
Lexis Advance Wins SIIA Business Technology CODiE Award
FTI Consulting Launches Specialist Director Support Services in the Cayman Islands
LexisNexis Spotlights New Innovations, Analytics & A.I. Offerings at AALL 2017
LexisNexis Digital Library Announces New Agreement with ALM
TRA Hires Tiffany Hanks as Regional Sales Consultant
LexisNexis® Expands Media Intelligence Portfolio with LexisNexis® Media Contacts Solution
LexisNexis Wins 21 Awards from Two Prestigious Publications

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)